Your browser doesn't support javascript.
loading
Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial.
Subbiah, Vivek; Kreitman, Robert J; Wainberg, Zev A; Gazzah, Anas; Lassen, Ulrik; Stein, Alexander; Wen, Patrick Y; Dietrich, Sascha; de Jonge, Maja J A; Blay, Jean-Yves; Italiano, Antoine; Yonemori, Kan; Cho, Daniel C; de Vos, Filip Y F L; Moreau, Philippe; Fernandez, Elena Elez; Schellens, Jan H M; Zielinski, Christoph C; Redhu, Suman; Boran, Aislyn; Passos, Vanessa Q; Ilankumaran, Palanichamy; Bang, Yung-Jue.
Afiliação
  • Subbiah V; Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. vsubbiah@mdanderson.org.
  • Kreitman RJ; Laboratory of Molecular Biology, National Institutes of Health, Bethesda, MD, USA.
  • Wainberg ZA; Department of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
  • Gazzah A; Drug Development Department (DITEP), Gustave Roussy Cancer Institute, Villejuif, France.
  • Lassen U; Department of Oncology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
  • Stein A; Department of Internal Medicine II (Oncology Center), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Wen PY; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Dietrich S; University of Heidelberg, Heidelberg, Germany.
  • de Jonge MJA; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
  • Blay JY; Center Leon Berard & University Claude Bernard Lyon I, Lyon, France.
  • Italiano A; Early Phase Trials and Sarcoma Units, Institut Bergonié, Bordeaux, France; Faculty of Medicine, University of Bordeaux, Bordeaux, France.
  • Yonemori K; National Cancer Center Hospital, Tokyo, Japan.
  • Cho DC; New York Medical College, Valhalla, NY, USA.
  • de Vos FYFL; Department of Medical Oncology, University Medical Center Utrecht, University Utrecht, Utrecht, The Netherlands.
  • Moreau P; Department of Hematology, CHU de Nantes, Nantes, France.
  • Fernandez EE; Department of Medical Oncology, Vall d'Hebron University Hospital (HUVH), Vall d'Hebron Institute of Oncology (VHIO), IOB-Quiron, UVic-UCC, Barcelona, Spain.
  • Schellens JHM; Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Zielinski CC; Medical University of Vienna, Vienna, Austria.
  • Redhu S; Global Program Biostatistics, Novartis Oncology, Cambridge, MA, USA.
  • Boran A; Global Drug Development, Oncology Development Unit, Novartis Services, Inc., East Hanover, NJ, USA.
  • Passos VQ; Global Drug Development, Oncology Development Unit, Novartis Services, Inc., East Hanover, NJ, USA.
  • Ilankumaran P; Global Drug Development, Oncology Development Unit, Novartis Services, Inc., East Hanover, NJ, USA.
  • Bang YJ; Seoul National University College of Medicine, Seoul, Republic of Korea.
Nat Med ; 29(5): 1103-1112, 2023 05.
Article em En | MEDLINE | ID: mdl-37059834
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Adenocarcinoma / Glioma Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Adenocarcinoma / Glioma Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article